Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy
Public ClinicalTrials.gov record NCT00104338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Proof of Concept, Randomized, Open-label, Two-arm, Parallel Group, Multi-center Study to Assess the Efficacy and Safety of FK778 Compared With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy
Study identification
- NCT ID
- NCT00104338
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- FK778 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2004
- Primary completion
- Not listed
- Completion
- Jul 31, 2006
- Last update posted
- Jun 6, 2012
2005 – 2006
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90057 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | San Francisco | California | 94143 | — |
| Not listed | Denver | Colorado | 80262 | — |
| Not listed | Washington D.C. | District of Columbia | 20010 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Jacksonville | Florida | 32216 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Wichita | Kansas | 67214 | — |
| Not listed | Baltimore | Maryland | 21287 | — |
| Not listed | New Brunswick | New Jersey | 08901 | — |
| Not listed | Durham | North Carolina | 22710 | — |
| Not listed | Cincinnati | Ohio | 45267 | — |
| Not listed | Harrisburg | Pennsylvania | 17104 | — |
| Not listed | Memphis | Tennessee | 38014 | — |
| Not listed | Salt Lake City | Utah | 84132 | — |
| Not listed | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00104338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2012 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00104338 live on ClinicalTrials.gov.